Advanced search
Publication Cover
Future Oncology Volume 18, 2022 - Issue 6
Submit an article Journal homepage
1,831
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion

Wu Di1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142ChinaORCID Iconhttps://orcid.org/0000-0002-6993-8350
ORCID Icon,
Cong Yue2 Department of Ultrasound,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142,China
,
Zhang Ziran1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Zhang Jie1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Nie Jun1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Dai Ling1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Hu Weiheng1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Chen Xiaoling1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Ma Xiangjuan1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Tian Guangming1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Han Jindi1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Han Sen1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Wang Yang1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
,
Long Jieran1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142China
&
Fang Jian1 Department of Thoracic Oncology II,Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute,Beijing,100142ChinaCorrespondence[email protected]
 show all
Pages 669-677 | Received 19 Aug 2021, Accepted 21 Oct 2021, Published online: 26 Jan 2022

References

  • van de Molengraft FJ , VooijsGP. Survival of patients with malignancy-associated effusions. Acta. Cytol.33(6), 911–916 (1989).
  • Porcel JM , GasolA, BielsaSet al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology20(4), 654–659 (2015).
  • Roberts ME , NevilleE, BerrisfordRGet al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax65(Suppl. 2), ii32–40 (2010).
  • Koegelenberg CFN , ShawJA, IrusenEMet al. Contemporary best practice in the management of malignant pleural effusion. Ther. Adv. Respir. Dis.12, doi:10.1177/1753466618785098 (2018).
  • Medford AR , MaskellNA. A national survey of oncologist and chest physicians’ attitudes towards empirical anti-oestrogen therapy, early pleurodesis and preference of sclerosing agent in malignant breast and ovarian pleural disease. Palliat. Med.19(5), 430–431 (2005).
  • Seto T , UshijimaS, YamamotoHet al. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br. J. Cancer95(6), 717–721 (2006).
  • Du N , LiX, LiFet al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol. Rep.29(6), 2332–2340 (2013).
  • Bates DO . Vascular endothelial growth factors and vascular permeability. Cardiovasc. Res.87(2), 262–271 (2010).
  • Grove CS , LeeYC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr. Opin. Pulm Med.8(4), 294–301 (2002).
  • Sabang RL , GandhirajD, FanucchiMet al. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev. Respir. Med.12(2), 87–94 (2018).
  • Chen Y , MathyNW, LuH. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol. Med. Rep.17(6), 8019–8030 (2018).
  • Chen D , SongX, ShiFet al. Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. Oncotarget8(21), 35262–35271 (2017).
  • Qi N , LiF, LiXet al. Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. Medicine (Baltimore).95(47), e5392 (2016).
  • Miller AB , HoogstratenB, StaquetMet al. Reporting results of cancer treatment. Cancer47(1), 207–214 (1981).
  • Ibitoye BO , IdowuBM, OgunrombiABet al. Ultrasonographic quantification of pleural effusion: comparison of four formulae. Ultrasonography37(3), 254–260 (2018).
  • Harris M , TaylorG. Medical statistics made easy.Martin Dunitz, London, UK, 48–52 (2003).
  • Nie K , ZhangZ, YouYet al. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac. Cancer11(1), 8–14 (2020).
  • Chen D , SongX, ZhangYet al. Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more. Future Oncol.14(21), 2131–2138 (2018).
  • Scappaticci FA , SkillingsJR, HoldenSNet al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst.99(16), 1232–1239 (2007).
  • Hirsh V . Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clin. Lung Cancer9(Suppl. 2), S62–70 (2008).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.